Budget
€10 — €0
EP Access
0
accredited persons
Staff
2
0.2 FTE
EU Grants
€2,199,999
Mission & Goals
ErVimmune develops breakthrough immunotherapies based on the identification of a new class of tumor antigens, Human endogenous retrovirus (HERVs) shared across tumors and patients. For the identification of those unconventional antigens, we have develop a proprietary framework: starting from the data and using AI tools and validation through biology tests.
EU Legislative Interests
Making submissions on the market strategy in pharma Answer to consultation : - EC EU Start-up and Scale-up Strategy - Single market strategy Participate to workshop : EIC Communities - Health Community of Practice and Women’s Health Working Sessions Participate to conferences
Communication Activities
EIC Summit on April EIC ePitch
Interests Represented
Promotes their own interests or the collective interests of their members
Member Of
BPI France CLARA EIC Accelerator
Additional Information
Registre de transparence de l'UE : 488647147874-39
Commissioner Meetings
No recorded meetings with EU commissioners.